← Back to guidelines
Pediatrics9 papers

Cardiospondylocarpofacial syndrome

Last edited: 4/16/2026

Overview

Cardiospondylocarpofacial syndrome, often associated with microduplications in the 22q11.2 region, presents a spectrum of clinical features overlapping with but distinct from DiGeorge/velocardiofacial syndrome (DG/VCFS). It involves duplications ranging from 3-4 Mb to 6 Mb, typically mediated by low-copy repeats (LCRs). 1

Diagnosis

  • Key Diagnostic Criteria: Microduplication in 22q11.2 identified via interphase fluorescence in situ hybridization (FISH) using bacterial artificial chromosome and P(1) artificial chromosome probes.
  • Recommended Tests: FISH analysis with multiple probes to confirm duplication size and involvement of LCRs.
  • Phenotypic Features: Velopharyngeal insufficiency, variable severity of symptoms including distinctive characteristics beyond those seen in DG/VCFS.
  • Molecular Confirmation: Short tandem repeat analysis to verify duplication size and presence of three alleles at least at one locus. 1
  • Management

  • First-Line Treatments: Address specific symptoms such as velopharyngeal insufficiency with surgical interventions (e.g., pharyngoplasty) as needed.
  • Adjunctive Therapies: Speech therapy for velopharyngeal dysfunction; genetic counseling for families.
  • No Specific Drug Doses Mentioned: Management focuses on symptomatic relief and supportive care tailored to individual patient needs. 1
  • Special Populations

  • Pediatrics: Early intervention for speech and feeding difficulties is crucial. 1
  • Comorbidities: Management should consider overlapping conditions like those seen in DG/VCFS, requiring multidisciplinary care. 1
  • Key Recommendations

  • Confirm diagnosis of 22q11.2 microduplication syndrome using FISH with multiple probes to assess duplication size and LCR involvement. (Evidence: Moderate) 1
  • Implement speech therapy and consider surgical interventions for velopharyngeal insufficiency in affected pediatric patients. (Evidence: Expert opinion) 1
  • Provide genetic counseling to families given the potential for variable expressivity and recurrence risks. (Evidence: Expert opinion) 1
  • References

    1 Ensenauer RE, Adeyinka A, Flynn HC, Michels VV, Lindor NM, Dawson DB et al.. Microduplication 22q11.2, an emerging syndrome: clinical, cytogenetic, and molecular analysis of thirteen patients. American journal of human genetics 2003. link

    Original source

    1. [1]
      Microduplication 22q11.2, an emerging syndrome: clinical, cytogenetic, and molecular analysis of thirteen patients.Ensenauer RE, Adeyinka A, Flynn HC, Michels VV, Lindor NM, Dawson DB et al. American journal of human genetics (2003)

    HemoChat

    by SPINAI

    Evidence-based clinical decision support powered by SNOMED-CT, Neo4j GraphRAG, and NASS/AO/NICE guidelines.

    ⚕ For clinical reference only. Not a substitute for professional judgment.

    © 2026 HemoChat. All rights reserved.
    Research·Pricing·Privacy & Terms·Refund·SNOMED-CT · NASS · AO Spine · NICE · GraphRAG